

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (original): A pharmaceutical composition for glycemic control of a type II diabetic patient, which is prepared for administration before meal and comprises mitiglinide or a pharmaceutically acceptable salt thereof, or a hydrate thereof, wherein the amount to be administered as a single dose is 5 to 45 mg.

2. (original): A pharmaceutical composition as claimed in claim 1 wherein the composition is prepared for administration just before meal.

3. (currently amended): A pharmaceutical composition as claimed in claim 1 ~~or 2~~ wherein the composition is to be administered three times a day before each meal for 4 weeks or more.

4. (currently amended): A pharmaceutical composition as claimed in claim 1 ~~any of claims 1 to 3~~ wherein the amount to be administered as a single dose is 5 to 22 mg.

PRELIMINARY AMENDMENT

5. (currently amended): A pharmaceutical composition as claimed in ~~claim 4~~claim 1 wherein the amount to be administered as a single dose is 10 to 11 mg and the active ingredient is mitiglinide calcium salt hydrate.

6 (currently amended): A pharmaceutical composition as claimed in claim 1~~any of claims 1 to 5~~ wherein the dissolution time for 75% release in the first fluid of the Japanese Pharmacopoeia is 20 minutes or less.

7. (currently amended): A pharmaceutical composition as claimed in claim 1~~any of claims 1 to 6~~ wherein the composition is an agent for prevention or treatment of type II diabetes.

8. (currently amended): A pharmaceutical composition as claimed in ~~claim 7~~claim 1 wherein the composition is an agent for prevention of type II diabetes which is a postprandial hyperglycemia.

9. (currently amended): A use of a pharmaceutical composition as claimed in claim 1~~any of claims 1 to 6~~ for glycemic control of a type II diabetic patient.

10. (currently amended): A use of a pharmaceutical composition as claimed in claim 1~~any of claims 1 to 7~~ for prevention or treatment of type II diabetes.

PRELIMINARY AMENDMENT

11. (currently amended): A use as claimed in claim ~~110~~ wherein the type II diabetes is a postprandial hyperglycemia.

12. (currently amended): A method for glycemic control of a type II diabetic patient, which comprises administering before meal 5 to 45 mg of mitiglinide or a pharmaceutically acceptable salt thereof, or a hydrate thereof, as a single dose.

13. (original): A method for glycemic control as claimed in claim 12 wherein the single dose is 5 to 22 mg.

14. (currently amended): A method for glycemic control as claimed in claim ~~143~~ wherein the single dose is 10 to 11 mg and the active ingredient is mitiglinide calcium salt hydrate.

15. (currently amended): A method for glycemic control as claimed in claim 12~~any of claims 12 to 14~~ wherein the type II diabetes is a postprandial hyperglycemia.

16. (currently amended): A method for improvement of postprandial hyperglycemia of a type II diabetic patient, which comprises administering before meal 5 to 45 mg of mitiglinide or a pharmaceutically acceptable salt thereof, or a hydrate thereof, as a single dose.

PRELIMINARY AMENDMENT

17. (original): A method for improvement as claimed in claim 16 wherein the single dose is 5 to 22 mg.

18. (currently amended): A method for improvement as claimed in claim ~~16~~¹⁷ wherein the single dose is 10 to 11 mg and the active ingredient is mitiglinide calcium salt hydrate.

19. (currently amended): A method for improvement as claimed in claim 12~~any of claims 12 to 18~~ wherein the number of doses a day is three.

20. (currently amended): A method for improvement as claimed in claim 12~~claim 19~~ wherein the treatment period is 4 weeks or more.

Claim 21 (canceled).

22. (new): A method for improvement as claimed in ~~any of~~ claim 16 wherein the number of doses a day is three.

23. (new): A method for improvement as claimed in claim 16 wherein the treatment period is 4 weeks or more.